Condition: NHL · DLBCL - Diffuse Large B Cell Lymphoma · Sponsor: University Medical Center Groningen
A phase II, multi-center study to compare the feasibility, and clinical efficacy of local manufacturing of CD19-directed CAR T-cells (ARI-0001 CAR T-cells) with commercial produced CAR T-cells (for example axicabtagene ciloleucel, a CD19 targeting commercially available CAR T-cell) in patients with relapsed or refractory (R/R) DLBCL.
This description comes directly from the study's public registry record.
T. (Tom) van Meerten · +31 (0)10 7041560 · hdc@erasmusmc.nl
Always discuss trial participation with your own doctor first.
| NL-Amsterdam-AMC | Amsterdam, Netherlands | Recruiting |
| NL-Groningen-UMCG | Groningen, Netherlands | Recruiting |
| NL-Leiden-LUMC | Leiden, Netherlands | Recruiting |
| NL-Maastricht-MUMC | Maastricht, Netherlands | Recruiting |
| NL-Nijmegen-RADBOUDUMC | Nijmegen, Netherlands | Recruiting |
| NL-Rotterdam-ERASMUSMC | Rotterdam, Netherlands | Recruiting |
| NL-Utrecht-UMCUTRECHT | Utrecht, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05641428